Respiratory syncytial virus infection in patients with cancer: still more questions than answers.
Simon
Arne
A
Schildgen
Oliver
O
Panning
Marcus
M
Bode
Udo
U
Eis-Huebinger
Anna Maria
AM
D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D019337:Hematologic Neoplasms / Q000150:complications* / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007223:Infant; D008297:Male; D009369:Neoplasms / Q000150:complications* / Q000276:immunology / Q000628:therapy*; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000453:epidemiology* / Q000276:immunology; D012136:Respiratory Syncytial Viruses / Q000302:isolation & purification*; D012254:Ribavirin / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D012254:Ribavirin; D000069455:Palivizumab